表紙
市場調查報告書

腫瘤/癌症治療藥市場:全球機會分析及產業預測 藥物類別,各適應症 2018年 - 2025年

Oncology/Cancer Drugs Market by Drug Class Type and Indication: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

出版商 Allied Market Research 商品編碼 329491
出版日期 內容資訊 英文 252 Pages
商品交期: 2-3個工作天內
價格
腫瘤/癌症治療藥市場:全球機會分析及產業預測 藥物類別,各適應症 2018年 - 2025年 Oncology/Cancer Drugs Market by Drug Class Type and Indication: Global Opportunity Analysis and Industry Forecast, 2018 - 2025
出版日期: 2019年02月19日內容資訊: 英文 252 Pages
簡介

全球腫瘤/癌症治療藥市場在2017年估算為974億100萬美金。該市場在2018年∼2025年間,預測將以7.6%的年複合成長率成長,2025年達到1,765億900萬美元的規模。

本報告提供全球腫瘤/癌症治療藥市場相關調查,市場機會,成長及阻礙因素,各藥物類別、適應症、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 報告的說明
  • 相關利益者的主要好處
  • 主要的市場區隔
    • 報告刊登的主要企業清單
  • 調查方法
    • 二次調查
    • 一次調查
    • 分析工具及模式

第2章 摘要整理

  • 研究的主要調查結果
  • CXO的觀點

第3章 市場概要

  • 市場定義及範圍
  • 主要調查結果
    • 主要的投資品牌
    • 主要的勝利策略 2017年
  • 主要企業的地位 2017年
  • 波特的五力分析
  • 臨床試驗
  • 專利分析(2015年∼2018年)
    • 全球專利分析
    • 各年度:專利分析
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第4章 腫瘤/癌症治療藥市場:各類藥物

  • 概要
    • 市場規模及預測
  • 化療
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模及預測:各地區
    • 市場分析:各國
  • 目標療法
  • 免疫療法(生物學性療法)
  • 荷爾蒙療法

第5章 腫瘤/癌症治療藥市場:適應症

  • 概要
    • 市場規模與預測
  • 肺癌
    • 市場規模及預測:各地區
    • 市場佔有率分析:各國
  • 胃癌
  • 大腸癌症
  • 乳癌
  • 前列腺癌症
  • 肝臟癌症
  • 食道癌症
  • 子宮頸癌
  • 腎臟癌症
  • 膀胱癌
  • 其他

第6章 腫瘤/癌症治療藥市場:各地區

  • 概要
    • 市場規模及預測
  • 北美
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模及預測:各國
    • 市場規模及預測:各類藥物
    • 市場規模及預測:各標示
  • 歐洲
  • 亞太地區
  • 南美,中東及非洲

第7章 企業簡介

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON (Janssen Global Services, LLC,)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LI_15121

Title:
Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025.

Oncology Drugs Market Overview:

The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types, especially blood cancer (leukemia). Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth.

However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.A

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.A

Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Benefits for Oncology Drugs Market:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.A

A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.

The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Oncology Drugs Key Market Segments:

By Drug Class TypeA

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By IndicationA

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • India
  • China
  • Japan
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA
  • ListA ofA Key Players Profiled in theA Report
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson (Janssen Global Services, LLC,)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • Sanofi
  • Amgen Inc.
  • Bayer AG
  • Exelixis, Inc.

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
  • 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies, 2017
  • 3.3. Top player positioning, 2017
  • 3.4. Porters five forces analysis
  • 3.5. Clinical trials
  • 3.6. Patent analysis (2015-2018)
    • 3.6.1. Patent analysis, world
    • 3.6.2. Patent analysis, by year
  • 3.7. Market dynamics
    • 3.7.1. Drivers
      • 3.7.1.1. Rise in incidence of cancer across the globe
      • 3.7.1.2. Surge in global geriatric population
      • 3.7.1.3. Increase in government expenditures on healthcare
    • 3.7.2. Restraints
      • 3.7.2.1. Adverse effects associated with the use of cancer drugs
    • 3.7.3. Opportunities
      • 3.7.3.1. Untapped emerging economies
      • 3.7.3.2. Increase in number of pipeline drugs
    • 3.7.4. Impact Analyses

CHAPTER 4: ONCOLOGY/ CANCER DRUGS MARKET, BY DRUG CLASS TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Chemotherapy
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market analysis, by country
  • 4.3. Targeted Therapy
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market analysis, by country
  • 4.4. Immunotherapy (Biologic Therapy)
    • 4.4.1. Key market trends, growth factors, and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market analysis, by country
  • 4.5. Hormonal Therapy
    • 4.5.1. Key market trends, growth factors, and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market analysis, by country

CHAPTER 5: ONCOLOGY/ CANCER DRUGS MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Lung Cancer
    • 5.2.1. Market size and forecast, by region
    • 5.2.2. Market share analysis, by country
  • 5.3. Stomach Cancer
    • 5.3.1. Market size and forecast, by region
    • 5.3.2. Market analysis, by country
  • 5.4. Colorectal Cancer
    • 5.4.1. Market size and forecast, by region
    • 5.4.2. Market share analysis, by country
  • 5.5. Breast Cancer
    • 5.5.1. Market size and forecast, by region
    • 5.5.2. Market share analysis, by country
  • 5.6. Prostate Cancer
    • 5.6.1. Market size and forecast, by region
    • 5.6.2. Market share analysis, by country
  • 5.7. Liver Cancer
    • 5.7.1. Market size and forecast, by region
    • 5.7.2. Market share analysis, by country
  • 5.8. Esophagus Cancer
    • 5.8.1. Market size and forecast, by region
    • 5.8.2. Market share analysis, by country
  • 5.9. Cervical Cancer
    • 5.9.1. Market size and forecast, by region
    • 5.9.2. Market share analysis, by country
  • 5.10. Kidney Cancer
    • 5.10.1. Market size and forecast, by region
    • 5.10.2. Market share analysis, by country
  • 5.11. Bladder Cancer
    • 5.11.1. Market size and forecast, by region
    • 5.11.2. Market share analysis, by country
  • 5.12. Other Cancers
    • 5.12.1. Market size and forecast, by region
    • 5.12.2. Market share analysis, by country

CHAPTER 6: ONCOLOGY/ CANCER DRUGS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors, and opportunities
    • 6.2.2. Market size and forecast, by country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. U.S. oncology/cancer drugs market, by drug class type
      • 6.2.2.1.2. U.S. oncology/cancer drugs market, by indication
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Canada oncology/cancer drugs market, by drug class type
      • 6.2.2.2.2. Canada oncology/cancer drugs market, by indication
      • 6.2.2.3. Mexico
      • 6.2.2.3.1. Mexico oncology/cancer drugs market, by drug class type
      • 6.2.2.3.2. Mexico oncology/cancer drugs market, by indication
    • 6.2.3. Market size and forecast, by drug class type
    • 6.2.4. Market size and forecast, by indication
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors, and opportunities
    • 6.3.2. Market size and forecast, by country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Germany oncology/cancer drugs market, by drug class type
      • 6.3.2.1.2. Germany oncology/cancer drugs market, by indication
      • 6.3.2.2. France
      • 6.3.2.2.1. France oncology/cancer drugs market, by drug class type
      • 6.3.2.2.2. France oncology/cancer drugs market, by indication
      • 6.3.2.3. UK
      • 6.3.2.3.1. UK oncology/cancer drugs market, by drug class type
      • 6.3.2.3.2. UK oncology/cancer drugs market, by indication
      • 6.3.2.4. Italy
      • 6.3.2.4.1. Italy oncology/cancer drugs market, by drug class type
      • 6.3.2.4.2. Italy oncology/cancer drugs market, by indication
      • 6.3.2.5. Spain
      • 6.3.2.5.1. Spain oncology/cancer drugs market, by drug class type
      • 6.3.2.5.2. Spain oncology/cancer drugs market, by indication
      • 6.3.2.6. Rest of Europe
      • 6.3.2.6.1. Rest of Europe oncology/cancer drugs market, by drug class type
      • 6.3.2.6.2. Rest of Europe oncology/cancer drugs market, by indication
    • 6.3.3. Market size and forecast, by drug class type
    • 6.3.4. Market size and forecast, by indication
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors, and opportunities
    • 6.4.2. Market size and forecast, by country
      • 6.4.2.1. Japan
      • 6.4.2.1.1. Japan oncology/cancer drugs market, by drug class type
      • 6.4.2.1.2. Japan oncology/cancer drugs market, by indication
      • 6.4.2.2. China
      • 6.4.2.2.1. China oncology/cancer drugs market, by drug class type
      • 6.4.2.2.2. China oncology/cancer drugs market, by indication
      • 6.4.2.3. Australia
      • 6.4.2.3.1. Australia oncology/cancer drugs market, by drug class type
      • 6.4.2.3.2. Australia oncology/cancer drugs market, by indication
      • 6.4.2.4. India
      • 6.4.2.4.1. India oncology/cancer drugs market, by drug class type
      • 6.4.2.4.2. India oncology/cancer drugs market, by indication
      • 6.4.2.5. South Korea
      • 6.4.2.5.1. South Korea oncology/cancer drugs market, by drug class type
      • 6.4.2.5.2. South Korea oncology/cancer drugs market, by indication
      • 6.4.2.6. Rest of Asia-Pacific
      • 6.4.2.6.1. Rest of Asia-Pacific oncology/cancer drugs market, by drug class type
      • 6.4.2.6.2. Rest of Asia-Pacific oncology/cancer drugs market, by indication
    • 6.4.3. Market size and forecast, by drug class type
    • 6.4.4. Market size and forecast, by indication
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors, and opportunities
    • 6.5.2. Market size and forecast, by country
      • 6.5.2.1. Brazil
      • 6.5.2.1.1. Brazil oncology/cancer drugs market, by drug class type
      • 6.5.2.1.2. Brazil oncology/cancer drugs market, by indication
      • 6.5.2.2. Saudi Arabia
      • 6.5.2.2.1. Saudi Arabia oncology/cancer drugs market, by drug class type
      • 6.5.2.2.2. Saudi Arabia oncology/cancer drugs market, by indication
      • 6.5.2.3. South Africa
      • 6.5.2.3.1. South Africa oncology/cancer drugs market, by drug class type
      • 6.5.2.3.2. South Africa oncology/cancer drugs market, by indication
      • 6.5.2.4. Rest of LAMEA
      • 6.5.2.4.1. Rest of LAMEA oncology/cancer drugs market, by drug class type
      • 6.5.2.4.2. Rest of LAMEA oncology/cancer drugs market, by indication
    • 6.5.3. Market size and forecast, by drug class type
    • 6.5.4. Market size and forecast, by indication

CHAPTER 7: COMPANY PROFILES

  • 7.1. AbbVie Inc.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product Portfolio
    • 7.1.5. Business performance
    • 7.1.6. Key strategic moves and developments
  • 7.2. Astellas Pharma Inc.
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product Portfolio
    • 7.2.5. Business performance
  • 7.3. AstraZeneca PLC
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product Portfolio
    • 7.3.5. Business performance
    • 7.3.6. Key strategic moves and developments
  • 7.4. Bristol-Myers Squibb Company
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product Portfolio
    • 7.4.5. Business performance
    • 7.4.6. Key strategic moves and developments
  • 7.5. Celgene Corporation
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product type Portfolio
    • 7.5.5. Business performance
  • 7.6. F. HOFFMANN-LA ROCHE LTD.
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product portfolio
    • 7.6.5. Business performance
    • 7.6.6. Key strategic moves and developments
  • 7.7. JOHNSON & JOHNSON (Janssen Global Services, LLC,)
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product Portfolio
    • 7.7.5. Business performance
  • 7.8. Merck & Co., Inc.
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product Portfolio
    • 7.8.5. Business performance
    • 7.8.6. Key strategic moves and developments
  • 7.9. Novartis AG
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product Portfolio
    • 7.9.5. Business performance
  • 7.10. Pfizer Inc.
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product Portfolio
    • 7.10.5. Business performance

List of Tables

  • TABLE 01. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
  • TABLE 02. CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 20162023 ($MILLION)
  • TABLE 03. CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 20172025 ($MILLION)
  • TABLE 04. CANCER DRUGS FOR IMMUNOTHERAPY, BY REGION, 20172025 ($MILLION)
  • TABLE 05. CANCER DRUGS FOR HORMONAL THERAPY, BY REGION, 20172025 ($MILLION)
  • TABLE 06. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
  • TABLE 07. ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 08. ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 09. ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 10. ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 11. CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 12. ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 13. ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 14. ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 15. ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 16. ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 20172025 ($MILLION)
  • TABLE 17. ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY REGION, 20172025 ($MILLION)
  • TABLE 18. ONCOLOGY/CANCER DRUGS MARKET REVENUE, BY REGION, 20172025 ($MILLION)
  • TABLE 19. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 20. U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 21. U.S. CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 22. CANADA CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 23. CANADA CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 24. MEXICO CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 25. MEXICO CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 26. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
  • TABLE 27. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
  • TABLE 28. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 29. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 30. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 31. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 32. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 33. UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 34. UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 35. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 36. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 37. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 38. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 39. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 40. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 41. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
  • TABLE 42. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
  • TABLE 43. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 44. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 45. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 46. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 47. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 48. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 49. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 50. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 51. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 52. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 53. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 54. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 55. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 56. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
  • TABLE 57. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
  • TABLE 58. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
  • TABLE 59. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 60. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 61. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 62. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 63. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 64. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 65. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
  • TABLE 66. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
  • TABLE 67. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
  • TABLE 68. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
  • TABLE 69. ABBVIE: COMPANY SNAPSHOT
  • TABLE 70. ABBVIE: OPERATING SEGMENTS
  • TABLE 71. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 72. ASTELLAS: COMPANY SNAPSHOT
  • TABLE 73. ASTELLAS: PRODUCTS AND SERVICES
  • TABLE 74. ASTELLAS: PRODUCT PORTFOLIO
  • TABLE 75. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 76. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 77. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 78. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 79. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 80. CELGENE: COMPANY SNAPSHOT
  • TABLE 81. CELGENE: OPERATING SEGMENTS
  • TABLE 82. CELGENE : PRODUCT TYPE PORTFOLIO
  • TABLE 83. ROCHE: COMPANY SNAPSHOT
  • TABLE 84. ROCHE: OPERATING SEGMENTS
  • TABLE 85. ROCHE: PRODUCT TYPE PORTFOLIO
  • TABLE 86. J&J: COMPANY SNAPSHOT
  • TABLE 87. J&J: OPERATING SEGMENTS
  • TABLE 88. J&J: PRODUCT TYPE PORTFOLIO
  • TABLE 89. MERCK: COMPANY SNAPSHOT
  • TABLE 90. MERCK: OPERATING SEGMENTS
  • TABLE 91. MERCK: PRODUCT PORTFOLIO
  • TABLE 92. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 93. NOVARTIS: OPERATING SEGMENTS
  • TABLE 94. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 95. PFIZER: COMPANY SNAPSHOT
  • TABLE 96. PFIZER: OPERATING SEGMENTS
  • TABLE 97. PFIZER: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP WINNING STRATEGIES, 2015-2018
  • FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2015-2018
  • FIGURE 05. TOP WINNING STRATEGIES: NATURE AND TYPE, 2015-2018
  • FIGURE 06. TOP PLAYER POSITIONING, 2017
  • FIGURE 07. MODERATE BARGANING POWER OF BUYERS
  • FIGURE 08. HIGH BARGANING POWER OF SUPPLIERS
  • FIGURE 09. MODERATE THREAT OF SUBSTITUTION
  • FIGURE 10. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 11. HIGH COMPETITIVE RIVALRY
  • FIGURE 12. PATENTS REGISTERED/APPROVED IN THE WORLD, 2015-2018
  • FIGURE 13. PATENTS ANALYSIS BY YEAR, 2015 THROUGH 2018
  • FIGURE 14. WORLD POPULATION AGED 65 AND OVER (%)
  • FIGURE 15. IMPACT ANALYSES, ONCOLOGY/CANCER DRUGS MARKET
  • FIGURE 16. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2017 & 2025
  • FIGURE 17. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2017 & 2025
  • FIGURE 18. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR IMMUNOTHERAPY, BY COUNTRY, 2017 & 2025
  • FIGURE 19. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR HORMONAL THERAPY, BY COUNTRY, 2017 & 2025
  • FIGURE 20. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 21. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 22. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 23. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 24. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 25. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 26. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 27. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 28. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 29. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY COUNTRY, 2017 & 2025
  • FIGURE 30. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017 & 2025
  • FIGURE 31. EUROPEAN GERIATRIC POPULATION (ABOVE 65 YEARS), 2017
  • FIGURE 32. ABBVIE: NET SALES, 20152017 ($MILLION)
  • FIGURE 33. ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 34. ABBVIE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 35. ASTELLAS: SALES, 20152017 ($MILLION)
  • FIGURE 36. ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2017 (%)
  • FIGURE 37. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 38. ASTRAZENECA: REVENUE, 20152017 ($MILLION)
  • FIGURE 39. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 40. REVENUE, 20152017 ($MILLION)
  • FIGURE 41. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 42. CELGENE: REVENUE, 20152017 ($MILLION)
  • FIGURE 43. CELGENE: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 44. CELGENE: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 45. ROCHE: NET SALES, 20152017 ($MILLION)
  • FIGURE 46. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 47. ROCHE: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 48. J&J: REVENUE, 20152017 ($MILLION)
  • FIGURE 49. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 50. J&J: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 51. MERCK: NET SALES, 20152017 ($MILLION)
  • FIGURE 52. MERCK: NET SALES BY SEGMENT, 2017 (%)
  • FIGURE 53. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
  • FIGURE 54. NET SALES, 20152017 ($MILLION)
  • FIGURE 55. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 56. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 57. PFIZER: REVENUE, 20152017 ($MILLION)
  • FIGURE 58. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 59. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)